Group 1 - The core finding of the study indicates that the combination of ASC47 and semaglutide resulted in a weight loss effect that was enhanced by up to 56.2% compared to the placebo and semaglutide combination [1][2] - The ASC47-103 study was a randomized, double-blind, placebo-controlled trial conducted in the United States, involving 28 obese participants with a body mass index (BMI) of 30 kg/m² or higher [1] - The study aimed to evaluate the safety, tolerability, and efficacy of a single dose of ASC47 in three different dosages (10 mg, 30 mg, and 60 mg) in conjunction with semaglutide, with a treatment period of 4 weeks and a follow-up period of 6 weeks [1] Group 2 - The CEO of the company expressed satisfaction with the significant synergistic weight loss effects observed from the combination of the fat-targeting THRβ agonist ASC47 and the incretin therapy, which also greatly improved gastrointestinal tolerability [2] - This study serves as an important proof-of-concept and will provide critical data for the design of subsequent Phase IIb combination therapy studies targeting obesity and metabolic-associated fatty liver disease (MASH) [2]
歌礼制药-B(01672)：ASC47联合司美格鲁肽在肥胖受试者中较司美格鲁肽单药减重效果相对提升高达56.2%